Showing 2911-2920 of 5771 results for "".
- Opus Genetics Receives FDA Agreement Under SPA for Phase 3 Trial of APX3330 in DRhttps://modernod.com/news/opus-genetics-receives-fda-agreement-under-spa-for-phase-3-trial-of-apx3330-in-diabetic-retinopathy/2482587/Opus Genetics announced it has reached agreement with the FDA on a Special Protocol Assessment (SPA) for a phase 3 clinical trial evaluating oral APX3330 for the treatment of moderate to severe non-proliferative diabetic retinopathy (NPDR).
- Celltrion Receives Positive CHMP Opinion for Eylea Biosimilar in the European Unionhttps://modernod.com/news/celltrion-receives-positive-chmp-opinion-for-eylea-biosimilar-in-the-european-union/2482586/Celltrion announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted positive opinions and recommended marketing authorizations for three biosimilar candidates, including Eydenzelt (CT-P42, aflibercept). Eydenzel
- FDA Clears ViGeneron's IND for Novel mRNA Gene Therapy to Treat Stargardt Disease and Other Retinal Dystrophieshttps://modernod.com/news/fda-clears-vigenerons-ind-for-novel-mrna-trans-splicing-gene-therapy-vg801-to-treat-stargardt-disease-and-other-abca4-linked-retinal-dystrophies/2482585/ViGeneron announced that the FDA has cleared the investigational new drug (IND) application for the phase 1/2 study of VG801, a gene therapy candidate to treat Stargardt disease and other retinal dystrophies associated with mutations in the&n
- Eylea HD Phase 3 Trial Meets Primary Endpoint in Patients with RVOhttps://modernod.com/news/eylea-hd-phase-3-trial-meets-primary-endpoint-showing-improved-vision-with-extended-dosing-intervals-in-patients-with-rvo/2482583/Regeneron announced the primary endpoint was met in the phase 3 QUASAR trial investigating Eylea HD (aflibercept) injection 8 mg for the treatment of patients with macular edema following retinal vein occlusion (RVO), including those with central, branch and hemiretinal vein occlusions.
- EssilorLuxottica Acquires Espansione Group, Provider of Noninvasive Ophthalmic Medical Deviceshttps://modernod.com/news/essilorluxottica-acquires-espansione-group-provider-of-noninvasive-ophthalmic-medical-devices/2482581/Optical giant EssilorLuxottica announced it is acquiring Italy-based Espansione Group, a provider of noninvasive medical devices for the diagnosis and treatment of dry eye, ocular surface and retinal diseases. Financial terms of the deal were not disclosed. Esp
- Atsena Completes Dosing in Part A of Phase 1/2 Trial Evaluating Gene Therapy to Treat X-linked Retinoschisishttps://modernod.com/news/atsena-therapeutics-completes-dosing-in-part-a-of-phase-12-trial-evaluating-gene-therapy-atsn-201-to-treat-x-linked-retinoschisis/2482579/Atsena Therapeutics announced dosing has been completed in Part A of the LIGHTHOUSE study, a phase 1/2 clinical trial evaluating subretinal injection of ATSN-201 for the treatment of X-linked retinoschisis (XLRS). ATSN-201, a best-in-class gene therapy product candidate, leverages AAV.S
- Tenpoint and Visus Complete Mergerhttps://modernod.com/news/tenpoint-and-visus-complete-merger/2482576/Tenpoint Therapeutics and Visus Therapeutics announced the completion of their merger. “As we relaunch Tenpoint as a combined entity with Visus, we are excited to lead with a robust ophthalmology pipeline, starting with Brimochol PF, a near-term therapeutic medicine for presbyopia
- CellViva Appoints Three Ophthalmology Leaders to Board of Directorshttps://modernod.com/news/cellviva-appoints-three-ophthalmology-leaders-to-board-of-directors/2482577/CellViva, a biopharmaceutical company developing anti-vascular endothelial growth factor—anti-VEGF—therapy for pterygium, announced the appointment of three leaders in ophthalmology to its Board of Directors. According to CellViva, the new directors are: Ad
- Bausch + Lomb Acquires Elios Vision to Bolster Glaucoma Surgical Portfoliohttps://modernod.com/news/bausch-lomb-acquires-elios-vision-to-bolster-glaucoma-surgical-portfolio/2482575/Bausch + Lomb announced that an affiliate has acquired Elios Vision, developer of the ELIOS procedure, a minimally invasive glaucoma surgery (MIGS) procedure using an excimer laser. Financial terms of the deal were not disclosed. According to B+
- Iantrek Publishes 12-Month Results for its Bio-Interventional Uveoscleral Outflow Technologyhttps://modernod.com/news/iantrek-announces-publication-highlighting-12-month-results-for-its-bio-interventional-uveoscleral-outflow-technology/2482574/Iantrek has announced 1-year results for the first 100 eyes enrolled in the CREST Registry, a real-world, prospective, observational study evaluating bio-interventional procedures in patients with open-angle glaucoma (OAG). The findings,